{"transactions":[{"id":3885571,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":165547,"kind":"person","name":"Reynolds Donald Rogers","position":1,"cik":"0001687930","reported_name":"Reynolds Donald Rogers","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-22T20:15:05.000Z","date":"2018-06-20","kind":"grant","acquired":true,"shares":258171,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Mr. Reynolds was awarded options to purchase shares of Mateon Therapeutics, Inc. common stock, $0.01 par value per shares (the \"Stock Options\"), in connection with his service as a member of the Board of Directors pursuant to the Amended and Restated Mateon Therapeutics, Inc. 2015 Equity Incentive Plan and the Amended and Restated Non-Employee Director Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Stock Options will vest in full on June 20, 2019, subject to Mr. Reynolds' continued service on the Board of Directors as of such date."}],"balance_after":258171,"derivative":{"exercise_price":0.22,"expiration_date":"2024-06-20","underlying":"Common Stock","underlying_shares":258171},"source":{"system":"sec-edgar","filing":"0001209191-18-039176","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000120919118039176/doc4.xml","form_type":"4"}},{"id":3963505,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":165547,"kind":"person","name":"Reynolds Donald Rogers","position":1,"cik":"0001687930","reported_name":"Reynolds Donald Rogers","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock B Warrants (Right to Buy)","published_at":"2018-04-16T20:24:58.000Z","date":"2018-04-12","kind":"purchase","acquired":true,"shares":125000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within one Unit purchased by the reporting person for $50,000 per Unit pursuant to a Subscription Agreement between the reporting person and Mateon Therapeutics, Inc. (the \"Company\"), dated April 12, 2018 (the \"Subscription Agreement\"). Each Unit consists of (i) 250,000 shares of Common Stock of the Company, par value $0.01 per share (the \"Common Stock\"), (ii) an \"A\" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share and (iii) a \"B\" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Common Stock B Warrants shall become exercisable immediately following the Company's stockholders' approval of an increase in the number of the Company's authorized shares of Common Stock sufficient to cover the number of shares issuable upon the exercise of all of the Common Stock B Warrants issued pursuant to the Subscription Agreement (the \"Stock Authorization\"). The Company is obligated to effect the Stock Authorization no later than June 30, 2018 (the \"Authorization Date\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Common Stock B Warrants shall expire on the date that is two years after the Stock Authorization is effected (the \"Expiration Date\"). In the event that the Company fails to effect the Stock Authorization by the Authorization Date, the Expiration Date will be extended for two additional years."}],"balance_after":125000,"derivative":{"exercise_price":0.4,"underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001209191-18-024991","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/908259/000120919118024991/doc4.xml","form_type":"4"}},{"id":3963504,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":165547,"kind":"person","name":"Reynolds Donald Rogers","position":1,"cik":"0001687930","reported_name":"Reynolds Donald Rogers","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock A Warrants (Right to Buy)","published_at":"2018-04-16T20:24:58.000Z","date":"2018-04-12","kind":"purchase","acquired":true,"shares":125000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within one Unit purchased by the reporting person for $50,000 per Unit pursuant to a Subscription Agreement between the reporting person and Mateon Therapeutics, Inc. (the \"Company\"), dated April 12, 2018 (the \"Subscription Agreement\"). Each Unit consists of (i) 250,000 shares of Common Stock of the Company, par value $0.01 per share (the \"Common Stock\"), (ii) an \"A\" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share and (iii) a \"B\" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share."}],"balance_after":125000,"derivative":{"exercise_price":0.4,"exercise_date":"2018-04-12","expiration_date":"2020-04-12","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001209191-18-024991","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/908259/000120919118024991/doc4.xml","form_type":"4"}},{"id":3963503,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":165547,"kind":"person","name":"Reynolds Donald Rogers","position":1,"cik":"0001687930","reported_name":"Reynolds Donald Rogers","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-04-16T20:24:58.000Z","date":"2018-04-12","kind":"purchase","acquired":true,"shares":250000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within one Unit purchased by the reporting person for $50,000 per Unit pursuant to a Subscription Agreement between the reporting person and Mateon Therapeutics, Inc. (the \"Company\"), dated April 12, 2018 (the \"Subscription Agreement\"). Each Unit consists of (i) 250,000 shares of Common Stock of the Company, par value $0.01 per share (the \"Common Stock\"), (ii) an \"A\" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share and (iii) a \"B\" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share."}],"balance_after":280000,"source":{"system":"sec-edgar","filing":"0001209191-18-024991","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000120919118024991/doc4.xml","form_type":"4"}},{"id":4286212,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":165547,"kind":"person","name":"Reynolds Donald Rogers","position":1,"cik":"0001687930","reported_name":"Reynolds Donald Rogers","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-13T00:29:54.000Z","date":"2017-06-09","kind":"grant","acquired":true,"shares":121483,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Mr. Reynolds was awarded options to purchase shares of Mateon Therapeutics, Inc. common stock, $0.01 par value per share (the \"Stock Options\"), in connection with his service as a member of the Board of Directors pursuant to the Mateon Therapeutics, Inc. 2015 Equity Incentive Plan and the Amended and Restated Non-Employee Director Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Stock Options will vest in full on June 9, 2018, subject to Mr. Reynolds' continued service on the Board of Directors as of such date."}],"balance_after":121483,"derivative":{"exercise_price":0.51,"expiration_date":"2023-06-09","underlying":"Common Stock","underlying_shares":121483},"source":{"system":"sec-edgar","filing":"0001209191-17-039317","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000120919117039317/doc4.xml","form_type":"4"}},{"id":4515883,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":165547,"kind":"person","name":"Reynolds Donald Rogers","position":1,"cik":"0001687930","reported_name":"Reynolds Donald Rogers","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $.01 par value per share","published_at":"2016-12-20T21:15:44.000Z","date":"2016-12-16","kind":"purchase","acquired":true,"shares":9950,"price":0.355,"value":3532.25,"ownership":{"direct":true},"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001209191-16-156108","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/908259/000120919116156108/doc4.xml","form_type":"4"}},{"id":4515882,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":165547,"kind":"person","name":"Reynolds Donald Rogers","position":1,"cik":"0001687930","reported_name":"Reynolds Donald Rogers","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $.01 par value per share","published_at":"2016-12-20T21:15:44.000Z","date":"2016-12-16","kind":"purchase","acquired":true,"shares":7350,"price":0.35,"value":2572.5,"ownership":{"direct":true},"balance_after":20050,"source":{"system":"sec-edgar","filing":"0001209191-16-156108","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/908259/000120919116156108/doc4.xml","form_type":"4"}},{"id":4515881,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":165547,"kind":"person","name":"Reynolds Donald Rogers","position":1,"cik":"0001687930","reported_name":"Reynolds Donald Rogers","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $.01 par value per share","published_at":"2016-12-20T21:15:44.000Z","date":"2016-12-16","kind":"purchase","acquired":true,"shares":12700,"price":0.34,"value":4318.0,"ownership":{"direct":true},"balance_after":12700,"source":{"system":"sec-edgar","filing":"0001209191-16-156108","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000120919116156108/doc4.xml","form_type":"4"}},{"id":4573635,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":165547,"kind":"person","name":"Reynolds Donald Rogers","position":1,"cik":"0001687930","reported_name":"Reynolds Donald Rogers","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2016-10-27T20:24:03.000Z","date":"2016-10-25","kind":"grant","acquired":true,"shares":135612,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Mr. Reynolds was awarded options to purchase shares of Mateon Therapeutics, Inc. common stock, $0.01 par value per share (the \"Stock Options\"), in connection with his appointment to the Board of Directors pursuant to the Mateon Therapeutics, Inc. 2015 Equity Incentive Plan and the Amended and Restated Director Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Stock Options will vest in three equal annual installments on the first, second and third anniversary of the date of grant, subject to Mr. Reynolds' continued service on the Board of Directors as of such date."}],"balance_after":135612,"derivative":{"exercise_price":0.58,"expiration_date":"2022-10-25","underlying":"Common Stock","underlying_shares":135612},"source":{"system":"sec-edgar","filing":"0001209191-16-147149","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000120919116147149/doc4.xml","form_type":"4"}}]}